Ticagrelor versus clopidogrel in black patients with stable coronary artery disease prospective, randomized, open-label, multiple-dose, crossover pilot study

Circulation: Cardiovascular Interventions

Volumn 8, Issue 7, 2015, Pages

  Waksman, Ron ^a,b   Maya, Juan ^a,b   Angiolillo, Dominick J ^c,d   Carlson, Glenn F ^c,d   Teng, Renli ^a   Caplan, Richard J ^b   Ferdinand, Keith C ^a,c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

African Americans; clopidogrel; coronary artery disease; platelet function tests; ticagrelor

Indexed keywords

AR C 124910XX; CLOPIDOGREL; DRUG METABOLITE; GLUCOSE; TICAGRELOR; UNCLASSIFIED DRUG; ACETYLSALICYLIC ACID; ADENOSINE; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; APPLICATION SITE REACTION; ARTICLE; BLACK PERSON; BLOOD VESSEL INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; CONTUSION; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; EPISTAXIS; FEMALE; GLUCOSE BLOOD LEVEL; HEMORRHOID HEMORRHAGE; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MULTICENTER STUDY; MULTIPLE DRUG DOSE; MUSCULOSKELETAL PAIN; OPEN STUDY; PILOT STUDY; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN BRUISING; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; THROMBOCYTE;

ADENOSINE; AGED; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 84942778011     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.114.002232     Document Type: Article

References (36)

1. Pendyala LK, Torguson R, Loh JP, Devaney JM, Chen F, Kitabata H, Minha S, Barbash IM, Suddath WO, Satler LF, Pichard AD, Waksman R. Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention. Am Heart J. 2013;166:266-272. doi: 10.1016/j.ahj.2013.04.008.
2. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574-e651. doi: 10.1161/CIR.0b013e31823ba622.
3. Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost. 2010;104:471-484. doi: 10.1160/TH10-04-0232.
4. Sharma RK, Erickson SW, Sharma R, Voelker DJ, Reddy HK, Dod H, Marsh JD. Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department. Vasc Health Risk Manag. 2013;9:187-193. doi: 10.2147/VHRM.S43909.
5. Li YG, Ni L, Brandt JT, Small DS, Payne CD, Ernest CS II, Rohatagi S, Farid NA, Jakubowski JA, Winters KJ. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets. 2009;20:316-327. doi: 10.1080/09537100903046317.
6. Fong J, Cheng-Ching E, Hussain MS, Katzan I, Gupta R. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J Stroke Cerebrovasc Dis. 2011;20:227-230. doi: 10.1016/j. jstrokecerebrovasdis.2009.12.004.
7. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038-1047. doi: 10.1093/eurheartj/ehi754.
8. VAN Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7:1556-1565. doi: 10.1111/j.1538-7836.2009.03527.x.
9. Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19:209-219. doi: 10.1177/1074248413511693.
10. Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, Camoin-Jau L, Paganelli F, Dignat-George F, Guieu R. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63:872-877. doi: 10.1016/j.jacc.2013.09.067.
11. AstraZeneca LP. Brilinta Prescribing Information, Revised March 29, 2013. http://www1.astrazeneca-us.com/pi/brilinta.pdf. Accessed June 4, 2015.
12. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF; DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844-1851. doi: 10.1016/j.jacc.2007.07.053.
13. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852-1856. doi: 10.1016/j. jacc.2007.07.058.
14. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56:1456-1462. doi: 10.1016/j.jacc.2010.03.100.
15. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsn M; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. doi: 10.1056/NEJMoa0904327.
16. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol. 2006;28:315-322. doi: 10.1358/mf.2006.28.5.990205.
17. Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12 rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res. 2007;119:277-284. doi: 10.1016/j.thromres.2006.01.019.
18. Silln H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2299-2306. doi: 10.1016/j.jchromb.2010.06.018.
19. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577-2585. doi: 10.1161/CIRCULATIONAHA.109.912550.
20. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011;124:1132-1137. doi: 10.1161/CIRCULATIONAHA.111.029165.
21. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261-2273. doi: 10.1016/j.jacc.2013.07.101.
22. Husted SE, Storey RF, Bliden K, Tantry US, Himark L, Butler K, Wei C, Teng R, Gurbel PA. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSETOFFSET and RESPOND studies. Clin Pharmacokinet. 2012;51:397-409. doi: 10.2165/11599830-000000000-00000.
23. US Census Bureau. Annual Estimates of the Resident Population by Sex, Age, Race Alone or in Combination, and Hispanic Origin for the United States and States: April 1, 2010 to July 1, 2012. http://factfinder2.census. gov/bkmk/table/1.0/en/PEP/2012/PEPASR5H. Accessed June 4, 2015.
24. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-e292. doi: 10.1161/01.cir.0000441139.02102.80.
25. Ford ES. Trends in predicted 10-year risk of coronary heart disease and cardiovascular disease among U.S. adults from 1999 to 2010. J Am Coll Cardiol. 2013;61:2249-2252. doi: 10.1016/j.jacc.2013.03.023.
26. Kawachi I, Daniels N, Robinson DE. Health disparities by race and class: why both matter. Health Aff (Millwood). 2005;24:343-352. doi: 10.1377/hlthaff.24.2.343.
27. Corbie-Smith G, Thomas SB, Williams MV, Moody-Ayers S. Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med. 1999;14:537-546.
28. Farmer DF, Jackson SA, Camacho F, Hall MA. Attitudes of African American and low socioeconomic status white women toward medical research. J Health Care Poor Underserved. 2007;18:85-99. doi: 10.1353/hpu.2007.0008.
29. Hamilton LA, Aliyu MH, Lyons PD, May R, Swanson CL Jr, Savage R, Go RC. African-American community attitudes and perceptions toward schizophrenia and medical research: an exploratory study. J Natl Med Assoc. 2006;98:18-27.
30. US Food and Drug Administration. Clinical Trials Shed Light on Minority Health. FDA Consumer Health Information, April 2013. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm349063.htm. Accessed June 4, 2015.
31. National Medical Association. Project IMPACT (Increase Minority Participant and Awareness of Clinical Trials). http://impact.nmanet.org/. Accessed June 4, 2015.
32. Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, Gurbel PA. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010;3:556-566. doi: 10.1161/CIRCGENETICS.110.958561.
33. Lewis JP, Ryan K, OConnell JR, Horenstein RB, Damcott CM, Gibson Q, Pollin TI, Mitchell BD, Beitelshees AL, Pakzy R, Tanner K, Parsa A, Tantry US, Bliden KP, Post WS, Faraday N, Herzog W, Gong Y, Pepine CJ, Johnson JA, Gurbel PA, Shuldiner AR. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet. 2013;6:184-192. doi: 10.1161/CIRCGENETICS.111.964627.
34. Oestreich JH, Best LG, Dobesh PP. Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. Am Heart J. 2014;167:413-418. doi: 10.1016/j.ahj.2013.10.028.
35. Ahn SG, Yoon J, Kim J, Uh Y, Kim KM, Lee JH, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Lee SH, Tahk SJ, Choe KH. Genotype-And Phenotype-Directed Personalization of Antiplatelet Treatment in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Stenting. Korean Circ J. 2013;43:541-549. doi: 10.4070/kcj.2013.43.8.541.
36. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188-1199. doi: 10.1161/CIRCULATIONAHA.109.919456.